Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. Pfizer Analysts SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target. Broad Label, Increased Supply to Give Pfizer Dominant Market Position Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for its molnupiravir more than a month ahead of Pfizer, Porges said in a note. The analyst sees the increase in Pfizer’s expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink’s current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the …